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Comparison of health state utility estimates 
from instrument-based and vignette-based 
methods: a case study in kidney disease
Andrew H. Briggs1*, Vasily Belozeroff2 and David Feeny3
Abstract 
Objective: We take advantage of a rare occurrence when two different studies report on the estimation of quality of 
life utilities for the same health states to assess convergence of the reported measures. Health state utilities are impor-
tant inputs into health economic models that estimate the impact of new medical technologies using a common 
metric of health gain—the quality adjusted life-year.
Results: We find low concordance between the two measures which is concerning in that this could have important 
ramifications for health care decision making based on estimated cost-effectiveness. We explore possible reasons for 
the discrepancy between the two measures and draw implications for the design of future studies.
Keywords: Health-related quality of life, Quality adjusted life years (QALYs), Cost-effectiveness, Medical technology, 
Health technology assessment (HTA)
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Introduction
Quality adjusted life years (QALYs) are commonly used 
as a measure of overall health outcome in cost-utility 
analyses of medical technologies. QALYs combine life 
expectancy and quality of life in a common currency. 
Theoretical underpinnings of quality of life assessment 
suitable for estimating QALYs emphasize the need for a 
preference-based framework and contrast the implica-
tions of patients- vs. community-rated utilities [1–3]. In 
practice, when considering economic evaluation of medi-
cal therapies, sponsors are often confronted with the 
choice between the direct utility elicitation studies using 
standard gamble, visual analogue scale, time trade-off 
(TTO) approaches, and indirect utility elicitation in clini-
cal trials based on value sets [4, 5]. Direct utility measures 
would involve development of health state descriptions 
(vignettes), while the indirect utility measures would 
employ a generic preference-based instrument, e.g., 
EQ-5D-3L, HUI or others as a measure in clinical trials 
[6–8]. Value sets are defined for a given instrument, such 
as the EQ-5D, as a method to translate questionnaires 
into utility values [9]. They are also based on an elicita-
tion method, such as TTO, standard gamble, etc.
A recent report from an international task force offers 
considerations on utility assessment for healthcare tech-
nologies highlighting the need to align utility meas-
urement with the health states of the corresponding 
economic analysis [10]. We report on a comparison of 
utility estimates for the same set of health states intended 
to inform a cost-utility model in the context of end stage 
renal disease (ESRD). These utilities were estimated using 
two different methods: the EQ-5D-3L instrument in a 
clinical trial, and a vignette-based TTO method in a gen-
eral population. Our objective was to assess the general 
agreement among these methods using regression tech-
niques, and to discuss the implications for cost-utility.
Main text
Summary of the studies
The first of the two studies was a randomized controlled 
clinical trial that evaluated the effects of a drug therapy 
cinacalcet on clinical outcomes, including cardiovascular 
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events and fractures in patients treated for secondary 
hyperparathyroidism in end stage renal disease [11]. The 
EQ-5D-3L instrument was used in the trial at baseline 
and throughout a 5-year follow-up in over 3500 patients 
[6]. EQ-5D-3L health states associated with both acute 
(3  months post event) and chronic (3–12  months post 
event) were identified and valued using the UK-based 
EQ-5D-3L scoring system which is based on preference 
scores elicited using the TTO approach [12, 13].
The second study estimated the utilities of the same 
clinical events by surveying participants from the gen-
eral population. The participants were presented with 
vignettes describing health states based on the inputs 
from focus group work with patients and clinical experts.
Health-state descriptions (vignettes) for health states 
associated with chronic kidney disease (CKD) and a 
parathyroid hormone condition, secondary hyperpar-
athyroidism (SHPT), were developed based on literature 
review and a qualitative study involving 54 patients diag-
nosed with CKD and SHPT. The descriptions were then 
reviewed by three physicians who treat patients with 
CKD and SHPT. The description and methods for direct 
utility assessment using time tradeoff (TTO) were tested 
in a pilot study.
The vignettes described having CKD and SHPT with 
and without various cardiovascular or fracture outcomes 
both for the acute phase (the year during which the event 
occurred) and chronic phase (more than 1-year after the 
event). The vignettes described the disease, symptoms, 
the impact on physical and social activities, dialysis, and 
an event such as a heart attack. The time horizon for the 
TTO was 1  year. The TTO was administered in-person 
by a trained professional interviewer using the ping-
pong approach and scored as x/y where x is the dura-
tion of time in perfect health that the subject values as 
being equal to spending the full year, y, in the impaired 
health state described in the vignette. 199 members of 
the general population (18+; mean age 46.3 years; 54.8% 
female; 49.7% reporting no health conditions) were inter-
viewed; the group was not necessarily representative of 
the general adult population. Respondents were recruited 
through local newspaper (Toronto, Ontario, Canada) and 
online advertisements. Mean TTO scores and standard 
deviations were computed.
Study participants completed time trade-off interviews 
for both acute (a year including the event) and chronic 
(a year following the event) health states associated with 
clinical outcomes relevant to the same disease and treat-
ment population [14].
Results of the comparison
The comparison between the EQ-5D-3L derived utilities 
and the vignette-derived TTO utilities is presented in 
Fig. 1a, b). On average, utilities derived from EQ-5D-3L 
were higher than the utilities derived from the vignette 
study; average utility was 0.12 higher for EQ-5D-3L for 
chronic health states and 0.04 higher for acute health 
states. Several health states had excellent agreement 
across methods, namely, acute description of myocardial 
infarction, peripheral vascular disease, and hospitalized 
angina where the variation was within 4%. The event-free 
state had a major difference across methods (20%). Acute 
utility measures had a closer agreement than the chronic 
ones, with the exception of three states: Stroke, heart fail-
ure, and bone fracture (opposite direction). All chronic 
states were valued lower with the vignette-based method. 
An ordinary least squares (OLS) regression analysis of 
the two studies shows a 29% correlation between the 
EQ-5D-3L-derived and vignette-derived utility meas-
ures (Fig. 1c) for the overall data points. The correlation 
was somewhat stronger  (R2 = 32%) if the regression was 
restricted to chronic compared to acute states  (R2 = 23%), 
despite the larger average difference between the two 
studies for chronic states.
One of the greatest differences between the two studies 
was the ‘no event’ basic health state, which was 0.75 for 
the EQ-5D-3L based method, and 0.60 for the vignette-
based method. An alternative comparison that could 
remove some of the inherent differences between the 
studies would be to look at the ‘disutility’ of the events 
estimated as the utility of the estimated event states less 
the basic no-event utility. Average differences in acute 
and chronic disutility for EQ-5D-3L and TTO settings 
was 0.07 but now with the EQ-5D-3L showing the higher 
disutility. An OLS regression analysis of the two stud-
ies for the disutility outcome shows a 23% correlation 
between EQ-5D-3L-derived and vignette-derived meas-
ures now that the baseline utility has been removed. Of 
course, restricting to acute or chronic events does not 
alter the correlation reported for utility above, although 
for disutility it is the acute events that have the largest 
magnitude of difference between the measures.
Discussion
We compared utility estimates from two well-accepted 
methods assessing health state utilities to inform eco-
nomic analysis of medical interventions. Both the 
vignette-based and the instrument-based methods are 
theoretically correct, but the evidence is limited as to 
their convergence. An earlier review of health utility 
measures and elicitation noted that study population 
characteristics such as socioeconomic demographics 
and disease or health states should be taken into consid-
eration when deriving health utilities from vignettes [15]. 
Another study comparing community quality of well-
being (QWB) and patient-based preferences (TTO) for 
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health outcomes from randomized controlled trial data 
found that QWB preference scores were significantly 
lower than corresponding TTO scores, which may have 
important implications for estimating QALYs gained [16].
Utility score estimates derived from members of the 
general population may help approximate a societal view-
point, but the utility assessment involving a hypothetical 
health state is limited by the accuracy and level of detail 
in the health state descriptions. Additionally, including a 
label of the health state being described and the setting in 
which the vignettes are presented (online or in-person) 
may affect the respondents’ valuations of the state [17, 
18]. Direct utility elicitation using the TTO (i.e., based 
on vignettes) is considered appropriate/acceptable by 
some HTA bodies when EQ-5D-3L is not available, and 
TTO with a 10-year time horizon is the most frequently 
used approach among the direct techniques, because of 
greater comparability with the method used to develop 
the EQ-5D-3L scoring algorithm [19, 20].
Switching to disutility has a potentially important effect 
on both the estimated impact of clinical events and on 
cost-effectiveness. The calculation of disutility empha-
sizes the impact of clinical events and the importance 
of the baseline utility to which they are applied. In com-
paring the two studies, the large difference between the 
basic health state utility without the event was enough 
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Fig. 1 a–c Graphical comparison and regression analysis of EQ-5D-3L and Vignette-derived utilities
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to reverse the magnitude of the differences between the 
studies. Utilities look higher when using the EQ-5D-3L 
instrument, but that disutility of events was also higher 
due to the higher no-event utility.
We found a weak positive correlation between both the 
chronic and acute utility regressions (Fig. 1c). This means 
there is substantial unexplained variability demonstrated 
between the studies that are measuring the same health 
states, and that mapping between the two can only be 
weakly predicted. This is concerning as such large utility 
differences may impact QALY estimates when calculating 
cost effectiveness of drugs and other interventions. Thus, 
differences in utility methodologies may lead to vari-
abilities in ICER calculations when using EQ-5D-3L and 
vignette methods.
As there is no gold standard for utility measurement, 
our goal was not to “validate” a method but rather to 
compare, and we found that the methods were only 
weakly correlated. Importantly, there were no consistent 
differences other than the utility being lower for chronic 
sub-states for vignette-based method, which may reflect 
patient adaptation [10].
From a practical standpoint, it is reasonable to use a 
method that would be accepted by a specific decision-
maker. For instance, in a recent assessment of a novel 
therapy in end stage renal disease, the UK National Insti-
tute for Health & Care Excellence (NICE) had accepted 
the EQ-5D-3L based utilities in a cost-utility model [21]. 
If a clinical trial with a reasonable duration and health 
state measurement opportunity is being planned, then 
including an instrument in such a trial is a good strat-
egy—longitudinal data allow application of regression 
models to estimate health state utilities. Where such 
trials are not available, or have already been completed 
without a utility instrument, a bespoke study to collect 
utilities seems the only option. A vignette-based method 
would allow a detailed description of the health states, 
but will invariably introduce a level of subjectivity. This 
same situation may arise where valuation of acute health 
states is wanted but may not be practically assessed in 
actual patients. To reduce the level of subjectivity, one 
could argue that a standard battery of vignettes ought to 
be catalogued so research is consistent across studies.
There are some nuanced differences that one could 
describe as “you get what you measure” and “you get 
what you describe” for each of the methods. In other 
words, if one is able to include multiple EQ-5D-3L meas-
ures in a trial, then there are opportunities to explore the 
data in a way that is fitting an economic model. Simi-
larly, one can describe details in the vignettes to the level 
that helps discern details important for patients but not 
visible through a generic instrument, in time as well as 
in content. As a contrast, limited measurements of an 
instrument in a trial, like limited descriptions within 
vignettes, would hamper such flexibility on either side.
We recognize that the value set from Dolan et  al. has 
been heavily criticized in the past and has several issues. 
One particular issue is the use of a linear regression 
model for utility values [22]. Authorities such as NICE 
should consider the criticism of existing value sets, creat-
ing more appropriate ones, and provide strong guidance 
on which value sets to use. Furthermore, the findings of 
this analysis could suggest that it might be important that 
all utility values should be quantified based on a consist-
ent approach.
The comparison of the health states utilities in these 
two studies lies within a general realm of health states 
whose consequences would be fairly well understood and 
appreciated by the medical community and the general 
population when described as vignettes. In that sense, 
one would expect that the real experience of a health 
state measured by an instrument in patients would be 
comparable to a hypothetical imaginary experience by 
non-patients based on a description of this state, barring 
the adaptation aspect. A more nuanced health state that 
requires more details and that is not as readily known to 
a non-patient may call for a different approach, but that 
would challenge both vignette-based methods on the 
ground of complexity and added subjectivity, and the 
instrument-based approach on the grounds of sensitivity. 
These are important considerations for further research 
and methodological harmonization.
Limitations
It is important to note that there are nuances in the tem-
poral characteristics of the state definitions that may 
impact scores. There have been other analyses compar-
ing different ways of estimating utility values, and it is 
well known that different approaches may yield different 
values [23–25]. There may be more than one factor that 
contributes to the difference between two utility scores. 
These differences include but are not limited to instru-
ment vs. direct method, nuances in temporal definitions 
of the states, differences in the inclusion of events by 
severity (which may explain, for example, the difference 
in fracture utilities in our comparison), and differences in 
the general population vs. actual patients. In this paper, 
we use a generic (non-specific) measure, the EQ-5D-3L, 
whereas the direct elicitation method is more disease 
specific.
Abbreviations
QALY: quality adjusted life year; TTO: time trade-off; ESRD: end stage renal 
disease; SHPT: secondary hyperparathyroidism; QWB: quality of well-being.
Acknowledgements
Anjani Parikh helped prepare an earlier version of the manuscript.
Page 5 of 5Briggs et al. BMC Res Notes          (2019) 12:385 
Authors’ contributions
AHB analysed the data and wrote the first manuscript draft. VB and DF contrib-
uted to data interpretation and drafting of the manuscript. All authors read 
and approved the final manuscript.
Funding
Amgen provided funding for this study under a contract that did not restrict 
or veto publication. A representative of the funder (VB) is included as an 
author for the manuscript. All authors are responsible for the content of the 
manuscript which does not necessarily reflect the views of the funder.
Availability of data and materials
All data generated or analysed during this study are included in this published 
article.
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
Andrew Briggs and David Feeny were paid as consultants for this project by 
Amgen Inc. and Vasily Belozeroff is an employee of Amgen Inc.
Author details
1 William R Lindsay Chair of Health Economics, Health Economics and Tech-
nology Assessment, Institute of Health & Wellbeing, University of Glasgow, 1 
Lilybank Gardens, Glasgow G12 8RZ, Scotland, UK. 2 Amgen Inc., Thousand 
Oaks, CA, USA. 3 Department of Economics, McMaster University, Hamilton, 
ON, Canada. 
Received: 2 November 2018   Accepted: 26 June 2019
References
 1. Weinstein MC, Torrance G, McGuire A. QALYs: the basics. Value Health. 
2009;12:S5–9.
 2. Brazier J. Valuing health States for use in cost-effectiveness analysis. 
Pharmacoeconomics. 2008;26(9):769–79.
 3. Neumann PJ, Ganiats TG, Russell LB, Sanders GD, Siegel JE, Oxford 
University P. Cost-effectiveness in health and medicine. New York: Oxford 
University Press; 2017.
 4. Leidl R, Reitmeir P. An Experience-Based Value Set for the EQ-5D-5L in 
Germany. Value Health. 2017;20(8):1150–6.
 5. Leidl R, Reitmeir P. A value set for the EQ-5D based on experienced health 
states: development and testing for the German population. Pharmaco-
economics. 2011;29(6):521–34.
 6. EuroQol Group. EuroQol—a new facility for the measurement of health-
related quality of life. Health Policy. 1990;16(3):199–208.
 7. Torrance GW, Furlong W, Feeny D, Boyle M. Multi-attribute preference 
functions. Health Utilities Index. Pharmacoeconomics. 1995;7(6):503–20.
 8. Feeny D, Furlong W, Torrance GW, Goldsmith CH, Zhu Z, DePauw S, et al. 
Multiattribute and single-attribute utility functions for the health utilities 
index mark 3 system. Med Care. 2002;40(2):113–28.
 9. Longworth L, Rowen D. Mapping to obtain EQ-5D utility values for use in 
NICE health technology assessments. Value Health. 2013;16(1):202–10.
 10. Wolowacz SE, Briggs A, Belozeroff V, Clarke P, Doward L, Goeree R, et al. 
Estimating health-state utility for economic models in clinical stud-
ies: an ISPOR good research practices task force report. Value Health. 
2016;19(6):704–19.
 11. The EVOLVE Trial Investigators. Effect of cinacalcet on cardiovascular dis-
ease in patients undergoing dialysis. N Engl J Med. 2012;367(26):2482–94.
 12. Dolan P, Gudex C, Kind P, Williams A. A social tariff for EuroQol: results 
from a UK general population survey. York: University of York; 1995.
 13. Briggs AH, Parfrey PS, Khan N, Tseng S, Dehmel B, Kubo Y, et al. Analyzing 
health-related quality of life in the EVOLVE Trial: the joint impact of treat-
ment and clinical events. Med Decis Making. 2016;36(8):965–72.
 14. Davies EW, Matza LS, Worth G, Feeny DH, Kostelec J, Soroka S, et al. 
Health state utilities associated with major clinical events in the context 
of secondary hyperparathyroidism and chronic kidney disease requiring 
dialysis. Health Qual Life Outcomes. 2015;13:90.
 15. Hao Y, Wolfram V, Cook J. A structured review of health utility measures 
and elicitation in advanced/metastatic breast cancer. ClinicoEcon Out-
comes Res CEOR. 2016;8:293–303.
 16. Oldridge N, Furlong W, Perkins A, Feeny D, Torrance GW. Community or 
patient preferences for cost-effectiveness of cardiac rehabilitation: does it 
matter? Eur J Cardiovasc Prev Rehabil. 2008;15(5):608–15.
 17. Norman R, King MT, Clarke D, Viney R, Cronin P, Street D. Does mode of 
administration matter? Comparison of online and face-to-face adminis-
tration of a time trade-off task. Qual Life Res. 2010;19(4):499–508.
 18. Rowen D, Brazier J, Tsuchiya A, Young T, Ibbotson R. It’s all in the name, 
or is it? The impact of labeling on health state values. Med Decis Making. 
2012;32(1):31–40.
 19. National Institute of Health and Care Excellence (NICE) Decision Support 
Unit (DSU). Technical support document 11: alternatives to EQ-5D for 
generating health state utility values. London: National Institute of Health 
and Care Excellence (NICE); 2011.
 20. Boye KS, Matza LS, Feeny DH, Johnston JA, Bowman L, Jordan JB. Chal-
lenges to time trade-off utility assessment methods: when should you 
consider alternative approaches? Expert Rev Pharmacoecon Outcomes 
Res. 2014;14(3):437–50.
 21. National Institute for Health and Care Excellence. Etelcalcetide for treat-
ing secondary hyperparathyroidism. NICE Technology appraisal guidance; 
2017.
 22. Hunger M, Doring A, Holle R. Longitudinal beta regression models for 
analyzing health-related quality of life scores over time. BMC Med Res 
Methodol. 2012;12:144.
 23. Leidl R, Schweikert B, Hahmann H, Steinacker JM, Reitmeir P. Assessing 
quality of life in a clinical study on heart rehabilitation patients: how 
well do value sets based on given or experienced health states reflect 
patients’ valuations? Health Qual Life Outcomes. 2016;14:48.
 24. Little MH, Reitmeir P, Peters A, Leidl R. The impact of differences between 
patient and general population EQ-5D-3L values on the mean tariff 
scores of different patient groups. Value Health. 2014;17(4):364–71.
 25. Leidl R, Reitmeir P, Konig HH, Stark R. The performance of a value set for 
the EQ-5D based on experienced health states in patients with inflamma-
tory bowel disease. Value Health. 2012;15(1):151–7.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
